Product: Jakafi; Jakavi
Generic name: ruxolitinib
Companies: Incyte; Novartis
2015 sales: $1.01 billion
2022 sales: $3.10 billion
Current indications: polycythemia vera; myelofibrosis
Jakafi's inclusion in the top 15 list may be something of a surprise, given the news last year that Incyte was pulling the plug on the drug for solid tumors after two failed trials in prostate and colorectal cancer.
EvaluatePharma's data suggest there is still plenty of upside for the JAK inhibitor despite that setback—although a chunk of its predicted $2 billion in the next few years will likely come from graft-versus-host disease, a noncancer indication.
First approved by the FDA for the bone marrow disorder myelofibrosis (MF) in 2011, a follow-up green light in polycythemia vera (PV) in 2014 consolidated its position in rare blood cancers. Incyte saw sales rise more than 50% in the first half of the year, while Novartis—which has marketing rights outside the U.S.—reported a 44% increase.
Incyte CEO Hervé Hoppenot said in August that the company still has more than a decade of patent protection for Jakafi, with plenty of room for growth in MF and PV thanks to raised awareness of the two diseases and the benefit of starting treatment early. In November 2016, Gilead's potential rival to Jakafi, momelotinib, stumbled in phase 3 when used to treat patients with MF, giving Incyte more breathing room.